by The U.S. urea cycle disorders treatment market comprises drugs and supplements for the treatment of urea cycle disorders which are inherited auto-digestive conditions caused due to genetic defects in enzymes and transporters involved in the urea cycle. Urea cycle disorders affect the body’s ability to break down waste and can cause dangerous buildup of ammonia in the blood which can lead to brain damage, coma, or death if not treated properly. The market has seen significant growth in awareness levels regarding early diagnosis and availability of improved treatments.
The Global U.S. urea cycle disorders treatment Market is estimated to be valued at US$ 587.52 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the U.S. urea cycle disorders treatment are Kawasumi Laboratories Inc., Blood Purification Technologies Inc., AWAK Technologies Pte. Ltd, Triomed AB, Asahi Kasei Medical Vo. Ltd, US Kidney Research Corporation, Merit Medical Systems, NIPRO Medical Corporation, Fresenius SE & Co. KGaA.
The U.S. Urea Cycle Disorders Treatment Market Demand provides considerable opportunities for companies involved in development of newborn screening techniques, enzyme replacement therapies, and drugs for improved management of acute hyperammonemic crises.
Major players are focusing on expanding their geographic footprint to leverage growth opportunities in international markets through collaborations and acquisitions.
Market Drivers
The increasing prevalence of urea cycle disorders mainly driven by growing diagnosis rates is a major factor accelerating market revenue growth. As per sources, around 1 in 8,000 individuals in the U.S. suffer from some type of urea cycle disorder. Initiatives to spread awareness about benefits of newborn screening and availability of effective treatment options is also supporting the market expansion.
PEST Analysis
Political: The major political factor is the favorable regulatory policies for rare disease treatment in the US. The Orphan Drug Act of 1983 provides tax incentives and extended exclusivity periods for drugs that treat rare diseases.
Economic: The rising healthcare expenditure as a percentage of GDP in the US Urea Cycle Disorders Treatment Market opportunities for new treatment options. The ability to pay for expensive rare disease drugs also influences the market growth.
Social: Improved awareness through patient advocacy groups regarding urea cycle disorders boosts early diagnosis and treatment-seeking rate. Initiatives to educate physicians also encourage appropriate management of these rare genetic conditions.
Technological: Advancements in gene therapy, stem cell transplantation, and other novel therapeutic areas hold promise to transform treatment landscape. Research on individualized therapies tailored to specific genetic mutations further expands options.
Regional Analysis
North America holds the largest share of the global urea cycle disorders treatment market in terms of value, owing to the high healthcare expenditure and presence of major market players in the US.
Europe is considered as the second largest and fastest growing regional market supported by rising research funding and initiatives to develop orphan drugs. The approval and adoption of new therapies are expected to drive the market in the European region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.
About Author - Ravina Pandya
Ravina Pandya, a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
